You are here

Other content within Product Pipeline:

Product Pipeline

Product Pipeline

Our Medicines in Development

Pfizer is prioritizing its research and development efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, and vaccines. Through major research efforts across multiple modalities — including small molecules, biologics and vaccines — Pfizer is developing the medical solutions that will matter most to the people we serve. Specialized efforts in biosimilars as well as rare diseases also illustrate our dedication to developing and delivering innovative medicines and vaccines that will benefit patients around the world.

Key Innovative Programs in Registration / Phase 3

  • avelumab (PF-06834635) (MSB0010718C): Metastatic Merkel Cell Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, Ovarian Cancer, Renal Cell Carcinoma, Urothelial Cancer (in collaboration w/ Merck KGaA)
  • Crisaborole: Atopic Dermatitis
  • Ertugliflozin: Type 2 Diabetes (in collaboration w/ Merck)
  • Ibrance (palbociclib): High Risk Early Breast Cancer, Early Breast Cancer in Adjuvant Setting
  • MOD-4023: Adult Growth Hormone Deficiency (in collaboration w/ OPKO)
  • Rivipansel: Vaso-Occlusive Crisis Associated with Sickle Cell Disease
  • talazoparib (MDV3800): Breast Cancer
  • Tanezumab: OA Signs and Symptoms, Chronic Low Back Pain, Cancer Pain
  • Trumenba (MnB rLP2086): Meningococcal Serogroup B (ex-U.S.)
  • Vyndaqel (tafamidis meglumine): Cardiomyopathy
  • Xeljanz® (tofacitinib): Ulcerative Colitis, Psoriatic Arthritis
  • Xtandi (enzalutamide): Breast Cancer, Prostate Cancer

Key Biosimilars Programs in Registration / Phase 3

  • A potential biosimilar to Humira® (adalimumab): Rheumatoid Arthritis
  • A potential biosimilar to Avastin® (bevacizumab): Non-Small Cell Lung Cancer
  • A potential biosimilar to Epogen® and Procrit® (epotein alfa): Anemia
  • A potential biosimilar to Remicade® (infliximab): Rheumatoid Arthritis (ex-European Economic Area)
  • A potential biosimilar to Rituxan®/MabThera (rituximab): Follicular Lymphoma
  • A potential biosimilar to Herceptin® (trastuzumab): Breast Cancer

Key Programs in Phase 2

  • Coagulation Factor IX (F9): Hemophilia
  • Dekavil (IL-10 Inhibitor): Rheumatoid Arthritis
  • glasdegib (PF-04449913) (SMO Inhibitor): Acute Myeloid Leukemia
  • Ibrance (palbociclib): Squamous Cell Carcinoma of the Head and Neck
  • JAK 1 Inhibitor: Atopic Dermatitis
  • lorlatinib (PF-06463922) (ALK/ROS1): Non-Small Cell Lung Cancer
  • MOD-4023: Pediatric Growth Hormone Deficiency (in collaboration w/ OPKO)
  • Modulator of Dopamine Signaling: Parkinson's Disease
  • Myostatin Inhibitor: Duchenne Muscular Dystrophy
  • PDE10 Inhibitor: Huntington’s Disease
  • Prophylactic Vaccine for Clostridium difficile Colitis
  • Prophylactic Vaccine for Staphylococcus aureus
  • Xtandi (enzalutamide): Breast Cancer, Hepatocellular Carcinoma

 

Remicade® is a registered U.S. trademark of Janssen Biotech, Inc.; Rituxan® is a registered U.S. trademark of Biogen MA Inc.; MabThera is a trademark of F. Hoffmann La Roche AG; Avastin® and Herceptin® are registered U.S. trademarks of Genentech, Inc.; Humira® is a registered U.S. trademark of Abbvie Biotechnology Ltd.; Epogen® is a registered U.S. trademark of Amgen Inc.; Procrit® is a registered U.S. trademark of Johnson & Johnson